AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (AARD) to Filing of Securities Class Action

Hagens Berman Sobol Shapiro announced a pending securities class action against Aardvark Therapeutics (AARD), targeting investors who bought shares in the IPO period around Feb. 13, 2025 and/or during Feb. 13, 2025 to May 14, 2026. The filing notice does not specify financial damages or allegations in the excerpt, but it typically raises litigation overhang and potential risk to shareholder value. Expect modest downside/volatility risk for AARD as legal and disclosure liabilities become a pricing factor.

Analysis

This is less a fundamental shock than a valuation tax on a small-cap balance sheet. For a cash-burning biotech, the real transmission is not damages per se; it is higher perceived dilution risk, tighter follow-on financing terms, and a management-bandwidth drain that can delay execution on the next clinical or financing milestone. The market usually prices these cases first as sentiment events, then as capital-structure events if the company needs money before the legal process resolves.

The immediate tape reaction can be muted if investors view the complaint as boilerplate, but the 1-3 month window matters more: motion-to-dismiss headlines, insurer negotiations, and any disclosure around cash runway or planned capital raises. If AARD is forced to tap equity while the overhang is live, the discount can widen disproportionately versus the broader biotech group (XBI/IBB) because buyers demand compensation for both litigation uncertainty and execution risk. Six to eighteen months out, the case is typically a settlement/insurance story, so the stock can recover if the company can bridge the period without dilution.

The contrarian view is that the market may be overestimating ultimate legal leakage and underestimating how much of the economics are already absorbed by D&O coverage. If the complaint is weak and the company can show a long cash runway, this becomes a tradable nuisance rather than a thesis break. What would falsify the bearish read is any disclosure of ample liquidity, no need for a near-term offering, or a quick insurer backstop that removes dilution risk.

Key Decisions for Investors

• Underweight/avoid AARD until the complaint specifics and cash runway are visible; this is a bad setup for owning an early-stage biotech through a litigation overhang if a financing is within 6-9 months.
• If borrow is available and liquidity is adequate, initiate a market-neutral short AARD / long XBI basket trade over the next 1-3 months to isolate idiosyncratic legal and dilution risk; cover if AARD discloses >18 months of cash runway or no need for external capital.
• Use options rather than outright shorts if borrow is expensive: buy near-dated AARD put spreads on any relief rally into motion-to-dismiss/newsflow windows; risk is limited to premium, and the thesis is invalidated by insurer-backed resolution or a clean liquidity update.
• Set an alert for any 10-Q/8-K language on cash runway, legal accruals, or financing intent; if management signals an equity raise is likely, the trade shifts from litigation overhang to near-term dilution and becomes materially more negative.